TAUG Generates Record Quarterly E-Commerce Revenue for its 2nd Fiscal Quarter 2021 (Period: July 1 -- Sept. 30, 2020)
October 01 2020 - 9:38AM
InvestorsHub NewsWire
The Company Substantially
Exceeds its Previous Quarterly Record, of $62,864.06 in E-Commerce
Sales, Reported During its 1st Fiscal Quarter 2021
(Period: April 1 -- June 30, 2020)
NEW YORK, NY -- October 1, 2020 -- InvestorsHub NewsWire
-- Tauriga Sciences, Inc. (OTCQB: TAUG)
(“Tauriga” or the “Company”), a revenue generating, diversified
life sciences company, with a proprietary line of functional
“supplement” chewing gums (Flavors: Pomegranate, Blood Orange,
Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two
ongoing Biotechnology initiatives, today announced that its highest
margin business segment (E-Commerce), continues to demonstrate
meaningful levels of growth, momentum, and overall strength.
For its 2ndFiscal Quarter 2021 (Period: July 1 –
September 30, 2020), the Company generated record Quarterly sales –
with respect to its E-Commerce sales. The Company is
confident that its existing fulfillment infrastructure can handle
significant levels of additional growth, should that occur.
The Company has substantial levels of inventory on hand, for all of
its products and product lines (fully paid for).
The Company remains highly confident in its future growth
prospects and continues to receive an increasing number of
re-orders from both E-Commerce and Retail customers.
ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG)
is a revenue generating, diversified life sciences company, engaged
in several major business activities and
initiatives. The company manufactures and distributes
several proprietary retail products and product lines, mainly
focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles
market segment. The main product line, branded as
Tauri-Gum™, consists of a proprietary supplement chewing gum that
is both Kosher certified and Vegan formulated (CBD Infused
Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate) & (CBG
Infused Tauri-Gum™ Flavor: Peach-Lemon). The Company’s
commercialization strategy consists of a broad array of retail
customers, distributors, and a fast-growing E-Commerce business
segment (E-Commerce website: www.taurigum.com). Please visit our
corporate website, for additional information, as well as
inquiries, at http://www.tauriga.com
Complementary to the Company’s retail business, are its two
ongoing biotechnology initiatives. The first one relates
to the development of a Pharmaceutical grade version of Tauri-Gum™,
for nausea regulation (specifically designed to help patients that
are subjected to ongoing chemotherapy treatment). On
March 18, 2020, the Company announced that it filed a provisional
U.S. patent application covering its pharmaceutical grade version
of Tauri-Gum™. The Patent, filed with the U.S.P.T.O. is
Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND
METHODS OF TREATMENT”. The second one relates to a
collaboration agreement with Aegea Biotechnologies Inc. for the
co-development of a rapid, multiplexed, Novel Coronavirus
(COVID-19) test with superior sensitivity and
selectivity.
The Company is headquartered in New York City and operates a
regional office in Barcelona, Spain. In addition, the
Company operates a full time E-Commerce fulfillment center located
in LaGrangeville, New York.
DISCLAIMER -- Forward-Looking Statements
This press release contains certain “forward-looking statements”
as defined by the Private Securities Litigation Reform Act of 1995
which represent management’s beliefs and assumptions concerning
future events. These forward-looking statements are often indicated
by using words such as “may,” “will,” “expects,” “anticipates,”
believes, “hopes,” “believes,” or plans, and may include statements
regarding corporate objectives as well as the attainment of certain
corporate goals and milestones. Forward-looking statements are
based on present circumstances and on management’s present beliefs
with respect to events that have not occurred, that may not occur,
or that may occur with different consequences or timing than those
now assumed or anticipated. Actual results may differ materially
from those expressed in forward looking statements due
to known and unknown risks and uncertainties, such as are not
guarantees of general economic and business conditions, the ability
to successfully develop and market products, consumer and business
consumption habits, the ability to consummate successful
acquisition and licensing transactions, fluctuations in exchange
rates, and other factors over which Tauriga has little or no
control. Many of these risks and uncertainties are discussed in
greater detail in the “Risk Factors” section of Tauriga’s Form 10-K
and other filings made from time to time with the Securities and
Exchange Commission. Such forward-looking statements are made only
as of the date of this release, and Tauriga assumes no obligation
to update forward-looking statements to reflect subsequent events
or circumstances. You should not place undue reliance on these
forward-looking statements.
CONTACT:
Tauriga Sciences, Inc.
555 Madison Avenue, 5th Floor
New York, NY 10022
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Instagram: @taurigum
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Apr 2023 to Apr 2024